Moreover, although deletion of gut microbiota and supplementation with TUDCA were both useful for the treatment of AP, our third experiment showed that deletion of gut microbiota plus TUDCA supplementation resulted in no additional therapeutic effect, with gene expression analysis revealing that gut microbiota may participate in inhibition of intestinal FXR signaling via TUDCA. The gene discussed is NR1H4; the disease is alkaline phosphatase measurement.